NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

Opinion|Videos|January 24, 2024

Improving Outcomes in CLL with BTK Inhibitors: Navigating Adverse Events, Sustaining Treatment, and Future Outlook in Relapsed/Refractory Disease

Author(s)Mazyar Shadman, MD, MPH

Dr Shadman provides insightful discussion on optimizing outcomes with BTK inhibition in CLL through adverse event mitigation and sustaining treatment in later lines.

Episodes in this series

EP. 1 Factors for Consideration When Choosing a Treatment for Patients With CLL

EP. 1 Factors for Consideration When Choosing a Treatment for Patients With CLL

EP. 2 The Current Treatment Landscape in CLL With the Advent of Novel Therapy Agents

EP. 2 The Current Treatment Landscape in CLL With the Advent of Novel Therapy Agents

EP. 3 BTK Inhibitor Investigations in the Frontline Treatment of CLL: Updates from ASH 2023

EP. 3 BTK Inhibitor Investigations in the Frontline Treatment of CLL: Updates from ASH 2023

$EP. 4 Emergent Data from the ALPINE Trial Investigating Zanubrutinib in the Treatment of Relapsed/Refractory CLL$

EP. 4 Emergent Data from the ALPINE Trial Investigating Zanubrutinib in the Treatment of Relapsed/Refractory CLL

$EP. 5 The Evolving Treatment Landscape in Relapsed/Refractory CLL$

EP. 5 The Evolving Treatment Landscape in Relapsed/Refractory CLL

$EP. 6 Improving Outcomes in CLL with BTK Inhibitors: Navigating Adverse Events, Sustaining Treatment, and Future Outlook in Relapsed/Refractory Disease$

EP. 6 Improving Outcomes in CLL with BTK Inhibitors: Navigating Adverse Events, Sustaining Treatment, and Future Outlook in Relapsed/Refractory Disease

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

CTD402 Gains FDA Orphan Drug Designation in T-ALL and T-LBL

ByAndrea Eleazar, MHS

January 29th 2026

FDA Clears Larger Vial Size of Nelarabine Injection in T-ALL and T-LBL

ByAndrea Eleazar, MHS

January 28th 2026

Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL

January 28th 2026

Oncologists Weigh BTK/BCL2 Inhibitor Combinations in CLL

ByTargeted Oncology Staff

January 23rd 2026

PD-1/PD-L1 Blockade Strengthens Salvage Therapy in R/R ALL

ByAndrea Eleazar, MHS

January 22nd 2026

Latest CME

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

Benjamin P. Levy, MD; John O. Mascarenhas, MD; Tiffany A. Traina, MD, FASCO; Cathy Eng, MD, FACP, FASCO; John P. Leonard, MD

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

43rd Annual Miami Breast Cancer Conference®

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC

Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia

NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC

Neoadjuvant Pembrolizumab Achieves High pCR Rates in Desmoplastic Melanoma

Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer